OrbiMed’s Tenet Healthcare THC Stock Holding History

OrbiMed’s Portfolio THC Stock Details THC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-25,000	Closed	-$3.16M	–	126
2024 Q4	$3.16M	Buy	+25,000	New	+$3.72M	0.06%	95
2023 Q3	–	Sell	-100,000	Closed	-$8.14M	–	139
2023 Q2	$8.14M	Buy	+100,000	New	+$7.12M	0.15%	94

Other funds holding THC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

OrbiMed's THC Position: Q3 2025 in Review

OrbiMed sold out of Tenet Healthcare (THC) in Q3 2025, closing a stake of 465,000 shares — an estimated $81.8M sold.

OrbiMed first reported a position in THC in Q2 2016 and held it in 23 quarters. The position peaked at $156M in Q2 2024. 680 funds tracked by Wall St. Rank hold THC as of Q3 2025.

OrbiMed reported no remaining Tenet Healthcare position as of Q3 2025 after selling out during the quarter.
OrbiMed sold 465,000 Tenet Healthcare shares in Q3 2025, an estimated $81.8M.
OrbiMed first reported a position in Tenet Healthcare in Q2 2016 and held it in 23 quarters.
OrbiMed's Tenet Healthcare position peaked at $156M in Q2 2024.
680 funds tracked by Wall St. Rank held Tenet Healthcare as of Q3 2025.

Based on OrbiMed's 13F filing for Q3 2025, filed 14 Nov 2025.